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higher persistence, non-prescription medical costs were reduced
for patients who were more persistent with anti-TNFs. Future
analyses need to examine the inﬂuence of higher persistence on
clinical outcomes.
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OBJECTIVE: This study investigated the relationship between
persistence with antihypertensive drugs (AHT) and blood pres-
sure (BP) goal attainment in clinical practice. METHODS: From
the PHARMO record linkage system comprising, among others,
linked drug-dispensing and hospital records of >2 million inhab-
itants in The Netherlands, new users of AHT were identiﬁed in
the period 1999–2004. Patients with stage 1 hypertension (sys-
tolic BP of 140–159 mmHg and/or diastolic BP of 90–99 mmHg)
or stage 2 hypertension (systolic BP ≥160 and/or diastolic BP ≥
100 mmHg) in the period of 6 months before onset of AHT treat-
ment were included in the study. Only patients with a BP mea-
surement in the period of 6–12 months after treatment onset
were included in the ﬁnal study cohort. Persistence with AHT
was determined by summing the number of days of continuous
treatment (gaps between dispensings <30 days) from treatment
onset. The outcome of interest was the ﬁrst BP measurement in
the period of 6–12 months after start. Patients with a BP below
140/90 mmHg were deﬁned “at goal”. RESULTS: The study
included 1271 patients of whom 1103 (87%) had stage 2 hyper-
tension. About 36% of patients with stage 1 and 13% of patients
with stage 2 hypertension were at goal at the time of the ﬁrst BP
measurement in the period of 6–12 months after treatment onset.
Fifty-four percent of patients with stage 1 hypertension and 73%
of patients with stage 2 hypertension were persistent with AHT
at goal attainment. Persistent use of AHT was associated with a
1.7 times increased chance of BP goal attainment in stage 2
hypertensive patients (RRadj = 1.67; 95%CI: 1.13–2.46), but
not in stage 1 hypertensive patients (RRadj = 1.04; 95%CI:
0.69–1.58). CONCLUSION: Persistent use of AHT plays an
important role in BP goal attainment in clinical practice in stage
2 hypertensive patients.
AO4
ADHERENCE TO GASTROPROTECTION AND THE RISK 
OF NSAID-RELATED UPPER GASTROINTESTINAL
COMPLICATIONS
Van Soest E, Sturkenboom MC, Dieleman JP, Verhamme K,
Siersema PD, Kuipers E
Erasmus University Medical Center, Rotterdam,The Netherlands
OBJECTIVES: To investigate the association between the level of
adherence to GPAs and the risk of serious NSAID-related UGI
complications in patients using non-selective NSAIDs (nsN-
SAIDS). METHODS: A population based nested case-control
study was conducted within a cohort of new NSAID users with
at least one risk factor for a NSAID-related UGI complication
identiﬁed in the Dutch Integrated Primary Care Information data-
base between 1996–2005. Adherence to GPAs was calculated as
the proportion of NSAID treatment days covered (PDC) by a GPA
prescription. Multivariate conditional logistic regression analysis
was used to calculate adjusted odds ratios (OR) with 95% 
conﬁdence intervals (95%CI). RESULTS: Considering the most
recent episode of continuous nsNSAID use prior to the index date,
14.9% of the nsNSAID users received GPAs. Of these, 71.0%
had a PDC ratio >80% (full adherence), 22.0% PDC ratios
between 20–80% (partial adherence) and 7.0% being non-
adherent (PDC < 20%). The risk of a serious NSAID-related UGI
complication increased from 2.5 (95%CI: 1.0–6.7) in partially
adherent persons to 4.0 (95%CI: 1.2–13.0) in those with a PDC
< 20%. Considering the PDC level as a continuous measure, the
risk of a serious NSAID-related UGI complication increased with
16% (95%CI: 2–32%) with every 10% decrease in adherence.
Excluding H2RA users that were not adequately dosed for the
prevention of NSAID-related UGI complications; the risk was
increased 2.7-fold in patients that were partially adherent and
4.5-fold in patients that were non-adherent. CONCLUSION:
There is a strong relationship between the level of adherence to
gastroprotective medication and the risk of serious UGI compli-
cations in high-risk nsNSAID users. This underlines the need for
adequate patient instruction regarding adherence to GPAs and/or
the further development of ﬁxed combination strategies.
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OBJECTIVES: To compare results of alternative calibration
methods using a global model of human papillomavirus and cer-
vical cancer, adapted to the US setting. METHODS: We devel-
oped a mathematical model incorporating a Markov process
simulating six-month transitions between health states of HPV-
related cervical disease. We calibrated the model to primary 
endpoints, such as age-speciﬁc cervical cancer incidence and
mortality, and further used mathematical algorithms to ensure
model ﬁts to age-speciﬁc prevalence of cervical intraepithelial
lesions (CIN, grades 1–3). Calibration parameters consisted of
age- and HPV type-speciﬁc transition probabilities, and data on
US calibration targets and ranges for transition probabilities
were obtained through an extensive review of the published lit-
erature. Three methods of calibration were sequentially used to
calibrate the model: manual, random computer search, and
Nelder-Mead computer optimization algorithm. Maximum like-
lihood estimation and weighted mean percentage deviation were
used to evaluate the goodness-of-ﬁt of each calibration, alter-
nately. All calibration strategies were compared using percentage
difference from the optimal goodness-of-ﬁt score. RESULTS: The
uncalibrated model deviated from the optimal ﬁt by 62%, the
manual calibration by 20%, the random search by 13%, and 
the Nelder-Mead optimization by 10% when using maximum
likelihood as the goodness-of-ﬁt criteria. When using weighted
mean percentage deviation as the goodness-of-ﬁt criteria, the 
corresponding percentages were 39% (uncalibrated), 19%
(manual), 15% (random), and 11% (Nelder-Mead). Using
weighted mean percentage deviation, when compared to
maximum likelihood, as the goodness-of-ﬁt criteria resulted in 
a closer ﬁt to primary model endpoints, including cervical 
cancer incidence and mortality. CONCLUSION: Computerized
methods of model calibration such as the Nelder-Mead opti-
mization algorithm can substantially improve the predictive
validity of a pharmacoeconomic model. Careful selection of the
goodness-of-ﬁt criteria is necessary to ensure that the model is
calibrated according to research needs.
